Trial Profile
Feasibility Study of Adjuvant Enzalutamide for the Treatment of Early Stage AR(+) Triple Negative Breast Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 02 May 2023
Price :
$35
*
At a glance
- Drugs Enzalutamide (Primary)
- Indications Advanced breast cancer; Early breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- 26 Apr 2023 Planned End Date changed from 1 May 2023 to 1 May 2024.
- 26 Apr 2023 Planned primary completion date changed from 1 May 2023 to 1 May 2024.
- 20 Aug 2022 Results assessing the feasibility of adjuvant enzalutamide in early-stage androgen-receptor-positive triple-negative breast cancer, published in the Breast Cancer Research and Treatment.